Pavmed Inc (PAVM) Stock Price, Quote & News

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.pavmed.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

dmc4321 Mar. 17 at 6:43 AM

$LUCD & $PAVM @RetiredMD A LIE This is just a MASS TESTING EVENT. It is announced today Tuesday, and ends tomorrow Wednesday. “Go get the early testing, go get ahead of it and live a long life,” Turner said. Free screenings are available for St. George firefighters through WEDNESDAY." Expect more of this crap as Lishan and Dennis try and create a narrative of progress to make up for THE TOTAL LACK OF PROGRESS.

1 · Reply

chuckjackson Mar. 16 at 8:08 PM

$PAVM so is Lishan giving up control of pavm? Insiders hold 60+% (with Lishan having a large holding) of the 1.5M shares outstanding. Whoever owns the preferred shares will own 4.6M shares when converted which means they will then control pavm.

3 · Reply

dmc4321 Mar. 16 at 5:22 PM

$LUCD & $PAVM IT actually is NOT taking any longer than normal if you consider the FACTS and ignore the liars like @PortfolioMgmt23 1. RESUBMISSIONS both take longer as you need to get agreement with all parties that contributed to the original REJECTION that the quality of the information is sufficient to overturn that REJECTION. 2. They do NOT GET PRIORITY. Explicitly stated. And in a lot of cases are buried behind original submissions as the workload is less and a decision already exists. 3. During the CAC they discussed Cyted Healths real world PEER REVIEWED data as the Gold Standard, as EsoGuard does NOT HAVE EQUIVALENT data. EsoGuard is missing the most critical data as it has been submitted but has not been peer reviewed. Ask yourself this. Would CMS be embarassed and would peoples jobs be at risk if there was the EXACT data they need waiting for peer review but CMS jumped the gun and then the peer review process concluded that the data was NOT GOOD ENOUGH? JUST FACTS.

0 · Reply

Ironbow Mar. 16 at 12:22 PM

$LUCD $PAVM #Dave~#dmc4321 👇🏻🏆

0 · Reply

dmc4321 Mar. 16 at 5:27 AM

$LUCD & $PAVM Normally there would be a Press Release late this week to try and create a narrative of "Progress" before the Conference Call. Lishan and Dennis have pushed the CC back to Thursday from the usual Wednesday in the hope that draft approval will be announced, it wont BTW. I suggest you ask this series of questions as at this stage they look at retail shareholders as total cuckolds. 1. You said you would focus on testing patients that would be covered under the population at risk when Esoguard gets approved. You did 500 a qtr in Q1 & Q2 of 2025. How many did you do in Q3 and Q 4 of 2025? The vast majority of your tests were done in mass testing events (3 nurses 200 people tested) how many additional nurses and sales people do you need to hire immediately if you are only testing 10 patients per location as flights, hotels etc remain the same. Is it 50 nurses per 200 tests? What is the largest number of patients tested that paid the full rate $1983 in one day at one location?

0 · Reply

chuckjackson Mar. 12 at 9:27 PM

$PAVM strike one. Two at-bats left

1 · Reply

dmc4321 Mar. 12 at 7:10 PM

$LUCD & $PAVM All the PUMPERS are like children waiting for Santa Claus. Whats that sound, is that Santas sleigh on our roof. Here are the reasons based in logic as to why there is no draft LCD and why there wont be one for MONTHS! Primary motivations for the current >7-month post-CAC silence (ranked by likelihood based on policy and history): Awaiting peer-reviewed publication of the 12k real-world data (still on medRxiv as of today) — dominant factor. The manuscript directly addresses the clinical-utility gaps flagged at CAC. Drafting before it lands risks a visible backtrack in the Response-to-Comments article. Internal comparative synthesis of the Cytosponge/BEST3 “gold-standard” discussion in the transcript + technology-scope alignment across the four MolDX MACs. If, a BIF IF, the PUMPERS had read the CAC transcript they would have noted that it was CYTED HEALTH data that was discussed to support using it to triage and BEST3 was seen as the GOLD STANDARD.

1 · Reply

BigJuicy Mar. 12 at 3:20 PM

$PAVM $LUCD probablities of draft LCD release: realistic probability estimate: • Before May 2026: ~35% • May–July 2026: ~45% • Late 2026: ~20% Patience my friends

3 · Reply

Carter113 Mar. 11 at 10:27 PM

$LUCD $PAVM https://www.fox2detroit.com/video/fmc-2pr01vsut03zri69

0 · Reply

chuckjackson Mar. 11 at 6:17 PM

$PAVM we have 3 at-bats left. Need to hit a home run on one od them

0 · Reply

PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

LUCD

Mar 12, 2026, 9:01 AM EDT - 5 days ago

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

LUCD

Feb 4, 2026, 8:01 AM EST - 5 weeks ago

PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

LUCD

Jan 21, 2026, 3:40 PM EST - 7 weeks ago

Should you chase the rally in PAVmed stock after it quadrupled on Wednesday?

Jan 21, 2026, 8:00 AM EST - 7 weeks ago

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

LUCD

Dec 30, 2025, 9:01 AM EST - 2 months ago

PAVmed Announces Reverse Stock Split

Dec 9, 2025, 8:01 AM EST - 3 months ago

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

LUCD

Dec 5, 2025, 11:08 AM EST - 3 months ago

PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 20, 2025, 8:15 AM EST - 4 months ago

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

LUCD

Nov 13, 2025, 11:31 AM EST - 4 months ago

PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 8:15 AM EST - 4 months ago

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LUCD

Nov 13, 2025, 8:00 AM EST - 4 months ago

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

LUCD

Nov 12, 2025, 8:00 AM EST - 4 months ago

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

LUCD

Oct 30, 2025, 8:01 AM EDT - 4 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

LUCD

Oct 29, 2025, 8:01 AM EDT - 4 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

LUCD

Oct 15, 2025, 8:01 AM EDT - 5 months ago

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

LUCD

Oct 7, 2025, 8:01 AM EDT - 5 months ago

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

Sep 16, 2025, 8:01 AM EDT - 6 months ago

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

LUCD

Sep 11, 2025, 9:17 AM EDT - 6 months ago

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

LUCD

Sep 10, 2025, 8:00 AM EDT - 6 months ago

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

LUCD

Sep 9, 2025, 4:01 PM EDT - 6 months ago

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

LUCD

Sep 5, 2025, 9:16 AM EDT - 6 months ago

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

LUCD

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

LUCD

Aug 26, 2025, 8:01 AM EDT - 7 months ago

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

LUCD

Aug 14, 2025, 8:00 AM EDT - 7 months ago

PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

LUCD

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

LUCD

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

LUCD

Jul 31, 2025, 8:01 AM EDT - 8 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

LUCD

Jul 30, 2025, 8:01 AM EDT - 8 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

LUCD

Jul 30, 2025, 8:00 AM EDT - 8 months ago

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

LUCD

Jul 16, 2025, 7:31 AM EDT - 8 months ago

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

LUCD

Jun 24, 2025, 8:01 AM EDT - 9 months ago

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Jun 18, 2025, 12:02 PM EDT - 9 months ago

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

LUCD

Jun 3, 2025, 8:31 AM EDT - 10 months ago

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

May 27, 2025, 7:31 AM EDT - 10 months ago

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

LUCD

May 15, 2025, 1:58 PM EDT - 10 months ago

PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:01 AM EDT - 10 months ago

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 14, 2025, 8:01 AM EDT - 10 months ago

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

LUCD

May 1, 2025, 8:31 AM EDT - 11 months ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

LUCD

Apr 30, 2025, 8:31 AM EDT - 11 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

LUCD

Apr 24, 2025, 8:01 AM EDT - 11 months ago

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

LUCD

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

LUCD

Mar 27, 2025, 8:01 AM EDT - 1 year ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

LUCD

Mar 25, 2025, 11:08 AM EDT - 1 year ago

PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:01 AM EDT - 1 year ago

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 8:01 AM EDT - 1 year ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

LUCD

Mar 20, 2025, 8:31 AM EDT - 1 year ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

LUCD

Mar 18, 2025, 8:31 AM EDT - 1 year ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

LUCD

Mar 13, 2025, 7:36 AM EDT - 1 year ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

LUCD

Mar 10, 2025, 9:01 AM EDT - 1 year ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

LUCD

dmc4321 Mar. 17 at 6:43 AM

1 · Reply

chuckjackson Mar. 16 at 8:08 PM

3 · Reply

dmc4321 Mar. 16 at 5:22 PM

0 · Reply

Ironbow Mar. 16 at 12:22 PM

$LUCD $PAVM #Dave~#dmc4321 👇🏻🏆

0 · Reply

dmc4321 Mar. 16 at 5:27 AM

0 · Reply

chuckjackson Mar. 12 at 9:27 PM

$PAVM strike one. Two at-bats left

1 · Reply

dmc4321 Mar. 12 at 7:10 PM

1 · Reply

BigJuicy Mar. 12 at 3:20 PM

$PAVM $LUCD probablities of draft LCD release: realistic probability estimate: • Before May 2026: ~35% • May–July 2026: ~45% • Late 2026: ~20% Patience my friends

3 · Reply

Carter113 Mar. 11 at 10:27 PM

$LUCD $PAVM https://www.fox2detroit.com/video/fmc-2pr01vsut03zri69

0 · Reply

chuckjackson Mar. 11 at 6:17 PM

$PAVM we have 3 at-bats left. Need to hit a home run on one od them

0 · Reply

chuckjackson Mar. 11 at 6:16 PM

$PAVM the vote to convert preferred shares to common shares is already a done deal? According to chat bots, insiders hold at least 60-65% of the common

0 · Reply

Ironbow Mar. 11 at 2:44 PM

$LUCD $PAVM Ignore dmc4321, he knows the LCD is inbound and his rhetoric is only going to get crazier as he try’s to collect Karma👇🏻

0 · Reply

dmc4321 Mar. 11 at 2:35 PM

$LUCD & $PAVM @Investbythenumbers The PUMPERS whole investment thesis is that all EsoGuard requires is a draft LCD and then all they have to do is wait until they are all multi millionaires. Does that seem CHILDISH. Particulary as the history of diagnostic tests is that commercialization is MUCH MUCH harder than getting FDA or CMS approval. I have been saying for 6 MONTHS or more that CMS approval is a Q4 2026 or 1st Half 2027 event. While they PUMPERS have had weekly countdowns starting early October. To this day NONE of them have explicitly stated that "RECONSIDERATIONS" ALWAYS TAKE LONGER THAN INITIAL SUBMISSIONS. ALWAYS AND THATS A FACT1 But as $LUCD runs out of money in September 26 how MASSIVE will the dilution be. BTW mark this. Lishan and Dennis will NOT say on the Q4 2025 CC how many tests would be covered by CMS's 12 month look back rule as it blows up the whole "step on the gas narrative" And the PUMPERS are such cuckolds that they wont ask the question. Just wait and see.

0 · Reply

Researchpro Mar. 11 at 2:46 AM

$PAVM anyone calculated how many shares will be added to the current float with conversion of series D preferred stocks?

3 · Reply

Ironbow Mar. 10 at 10:28 AM

$LUCD $PAVM Dave ~ LPlates ~ dmc4321 — None of us were dumb enough to buy at the IPO like you. LMAO…. Enough said !!

1 · Reply

dmc4321 Mar. 10 at 2:36 AM

$LUCD & $PAVM Thank you for the kind words. I dont see it as a jihad as I believe in collecting Karma. When I first started out on my journey I benefitted from the generosity and advise of many on Biotwitter. They educated me for no other reason than they could and they wanted to. So this started out as a way of paying it back by paying it forward. It has gone on long long past what I thought and i have got irritable and short tempered. I suffered fools years ago, today I do not. I would guess that you too read the SEC filings and use them as the cornerstone of your due diligence. It amazes me how people will work so hard to save after tax dollars and then squander it all by just reading press releases and analyst reports. My very first investment was ILMN soon after IPO and on every CC Jay Flatley would layout in detail what he had said to measure, how they had performed against those metrics and what to expect in the next Qtr. Contrast that to Lishan & Dennis🤐 Once again thks

0 · Reply

chuckjackson Mar. 9 at 6:22 PM

$PAVM we have 3 more weeks left with the current low float

1 · Reply

Carter113 Mar. 7 at 9:26 PM

$LUCD $PAVM $LUCD $PAVM @dmc4321 @LPlates the record, if we are talking facts: Wrong on: Arynton May 22nd covenent PAVM needing to rely on Veris and/or LUCD to raise funds. And that is just in the last 6 months!!! Your a 🤡 that is constantly changing you bullshit scare tactics!!! Oh yes you also said LUCD is ONLY go to $2.50 Dave, think about how much of your horrible wasted life you have thrown away trying to scare people on this board! 7 figures + long and strong, and up over 40% so far! 🖕🫵 Dave!!!

2 · Reply

ConditionalInvesting Mar. 7 at 8:56 PM

$PAVM $LUCD please go away. sincerely, everyone.

0 · Reply

dmc4321 Mar. 7 at 7:56 PM

$PAVM $LUCD I was wrong, by a LOT. PAVM has traded at UNDER 1.5 CENTs. That is not a typo. I said LESS than 5 CENTS, and it actually has been one and one half of a CENT. So I was WRONG by more than 3X My bad. But I suppose if you had listened to me you might be happy? I think LUCD will spike in the trading day after CMS Draft approval but there is a $75M financing just waiting to go so that will kill any rally. But as soon as it becomes apparent that LUCD doesnt have any hope of sucess under Lishan and Dennis it will TRADE AT UNDER 50 CENTS. I was RIGHT then and I will be RIGHT in the future.

2 · Reply

Carter113 Mar. 7 at 6:28 PM

$LUCD $PAVM @dmc4321 @LPlates the record, if we are talking facts: Wrong on: Arynton May 22nd covenent PAVM needing to rely on Veris and/or LUCD to raise funds. And that is just in the last 6 months!!! Your a 🤡 that is constantly changing you bullshit scare tactics!!! Oh yes you also said LUCD is ONLY go to $2.50 Dave, think about how much of your horrible wasted life you have thrown away trying to scare people on this board! 7 figures + long and strong, and up over 40% so far! 🖕🫵 Dave!!!

0 · Reply

dmc4321 Mar. 7 at 5:22 PM

$LUCD & $PAVM Let me go on the record, so maybe I will be wrong on a major issue (I won't BTW) which will be a first. LUCD will trade BELOW 50 CENTS IN 2026. Those that have been around long enough know I have never been wrong and I am more sure of my UNDER 50 CENTS CALL than any other call or projection i have made. You guys do no due diligence, on top of which 95% do not understand diagnostics. So no research, no knowledge, no reasoning yet you expect to 5X your money. Do you know how STUPID you have to be to think that reading a press release or a stupid analysts report gives you knowledge and insight. You hide your head in the sand when you should be investigating any and all bad news. SUCCESS will not hurt you but LUCD's failure will. Manage the downside and let the upside look after itself is a well known investment phrase. You guys "believe the upside no matter how far fetched and ridiculous and ignore the downside because it makes me feel sad"

5 · Reply

Market Cap	10.03M
Revenue (ttm)	3.00M
Net Income (ttm)	39.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	1,326.33%
Debt to Equity Ratio	0.00

Volume	7,900
Avg Vol	1,244,886
Day's Range	N/A - N/A
Shares Out	984,000.00
Stochastic %K	24%
Beta	0.90
Analysts	Sell
Price Target	$285.25